After diagnosis, but before surgery, patients are considered for chemotherapy and radiation therapy depending on the state of their disease. This calculator will estimate the survival of a specific patient after they have completed their therapy based on their final pathologic stage.
Enter details below for a patient who has not yet had surgery for esophageal cancer to estimate the benefit received from neoadjuvant chemoradiotherapy rather than isolated surgery. The benefit of neoadjuvant therapy based on final pathologic stage may be underestimated due to variable stage drift and treatment effect.
Reference: Eil R, Diggs B, Wang SJ, Dolan J, Hunter JG, Thomas CR. Nomogram for predicting the benefit of neoadjuvant chemoradiotherapy for Patients with Esophageal Cancer - A SEER - Medicare analysis. Cancer, Volume 120, Issue 4, pages 492–498, 15 February 2014.